Agnes Perez-Millan
Overview
Explore the profile of Agnes Perez-Millan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Millan A, Lal-Trehan Estrada U, Falgas N, Guillen N, Borrego-Ecija S, Junca-Parella J, et al.
Eur Radiol
. 2025 Feb;
PMID: 39934339
Objectives: Frontotemporal dementia (FTD) usually shows more asymmetric atrophy patterns than Alzheimer's disease (AD). We aim to quantify this asymmetry to differentiate FTD, AD, and FTD subtypes. Methods: We studied...
2.
Sarto J, Esteller-Gauxax D, Guillen N, Falgas N, Borrego-Ecija S, Massons M, et al.
J Neurol
. 2025 Jan;
272(2):160.
PMID: 39849125
Plasma tau phosphorylated at threonine 181 (p-tau181) and 217 (p-tau217) have demonstrated high accuracy for Alzheimer's disease (AD) diagnosis, defined by CSF/PET amyloid beta (Aβ) positivity, but most studies have...
3.
Perez-Millan A, Thirion B, Falgas N, Borrego-Ecija S, Bosch B, Junca-Parella J, et al.
Neurobiol Aging
. 2024 Sep;
144:1-11.
PMID: 39232438
Neuroimaging and fluid biomarkers are used to differentiate frontotemporal dementia (FTD) from Alzheimer's disease (AD). We implemented a machine learning algorithm that provides individual probabilistic scores based on magnetic resonance...
4.
Falgas N, Pena-Gonzalez M, Val-Guardiola A, Perez-Millan A, Guillen N, Sarto J, et al.
Alzheimers Dement
. 2024 Jul;
20(9):6351-6364.
PMID: 39051173
Introduction: Early-onset Alzheimer's disease (EOAD) shows a higher burden of neuropsychiatric symptoms than late-onset Alzheimer's disease (LOAD). We aim to determine the differences in the severity of neuropsychiatric symptoms and...
5.
Alsina R, Riba M, Perez-Millan A, Borrego-Ecija S, Aldecoa I, Romera C, et al.
Acta Neuropathol Commun
. 2024 Jun;
12(1):97.
PMID: 38879502
Wasteosomes (or corpora amylacea) are polyglucosan bodies that appear in the human brain with aging and in some neurodegenerative diseases, and have been suggested to have a potential role in...
6.
Guillen N, Perez-Millan A, Falgas N, Lledo-Ibanez G, Rami L, Sarto J, et al.
Sci Rep
. 2024 Jun;
14(1):12927.
PMID: 38839833
We aimed to characterize the cognitive profile of post-acute COVID-19 syndrome (PACS) patients with cognitive complaints, exploring the influence of biological and psychological factors. Participants with confirmed SARS-CoV-2 infection and...
7.
Sarto J, Esteller-Gauxax D, Tort-Merino A, Guillen N, Perez-Millan A, Falgas N, et al.
J Neurol
. 2023 Dec;
271(4):1973-1984.
PMID: 38151575
Plasma biomarkers have emerged as promising tools for identifying amyloid beta (Aβ) pathology. Before implementation in routine clinical practice, confounding factors modifying their concentration beyond neurodegenerative diseases should be identified....
8.
Borrego-Ecija S, Perez-Millan A, Antonell A, Fort-Aznar L, Kaya-Tilki E, Leon-Halcon A, et al.
Alzheimers Dement
. 2023 Nov;
20(3):1515-1526.
PMID: 38018380
Introduction: Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study...
9.
Perez-Millan A, Borrego-Ecija S, Falgas N, Junca-Parella J, Bosch B, Tort-Merino A, et al.
J Neurol
. 2023 Nov;
271(3):1428-1438.
PMID: 38012398
Background And Objective: Alzheimer's disease (AD) and frontotemporal dementia (FTD) show different patterns of cortical thickness (CTh) loss compared with healthy controls (HC), even though there is relevant heterogeneity between...
10.
Rami L, Leon M, Valech N, Coll-Padros N, Bosch B, Olives J, et al.
Neuropsychology
. 2023 Feb;
37(6):683-697.
PMID: 36729500
Objective: Subtle decline in memory is thought to arise in the preclinical phase of Alzheimer's disease (AD). However, detecting these initial cognitive difficulties cross-sectionally has been challenging, and the exact...